SEC Form 4 · accession 0001209191-17-048408
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Daly
Officer — Chief Commercial Officer
Period of report
Aug 9, 2017
Accepted (ET)
Aug 10, 2017 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 9, 2017 | M | 46,872 | $22.24 | A | 163,133 | D | |
| Common StockF1 | Aug 9, 2017 | S | 46,872 | $39.50 | D | 116,261 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $22.24 | Aug 9, 2017 | M | 46,872 | D | — | Dec 5, 2024 | Common Stock | 46,872 | 28,128 | D |
Explanation of responses
- F1The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.05 to $40.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
- F2This option was granted on December 5, 2014 and is exercisable (i) with respect to 25% of the shares subject to the options, on November 30, 2015, and (ii) with respect to 6.25% of the shares subject to the option, on each subsequent three month period beginning February 28, 2016 until fully vested.